Vivos Therapeutics Q4 2023 GAAP EPS $(3.05) Misses $(1.91) Estimate, Sales $3.248M Miss $3.406M Estimate
Vivos Therapeutics Q4 2023 GAAP EPS $(3.05) Misses $(1.91) Estimate, Sales $3.248M Miss $3.406M Estimate
Vivos Therapeutics 2023年第四季度GAAP每股收益美元（3.05美元）未达到预期（1.91美元），销售额324.8万美元未达到34.06万美元的预期
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(3.05) per share which missed the analyst consensus estimate of $(1.91) by 59.69 percent. The company reported quarterly sales of $3.248 million which missed the analyst consensus estimate of $3.406 million by 4.64 percent. This is a 17.77 percent decrease over sales of $3.950 million the same period last year.
Vivos Therapeutics（纳斯达克股票代码：VVOS）公布的季度亏损为每股3.05美元（3.05美元），比分析师普遍预期的1.91美元（1.91美元）低59.69％。该公司公布的季度销售额为324.8万美元，比分析师普遍预期的34.06万美元低4.64％。这比去年同期的3950万美元销售额下降了17.77％。